Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alembic Q2 Gets Sartans Shot

Executive Summary

Continuing sartans crisis, new product launches in US help Alembic post strong Q2 performance despite slowdown in other markets.

You may also be interested in...



As US Slows Down, Torrent Aims For Germany, Brazil

A lack of new launches and price erosion caused a sharp dip in Torrent’s Q3 US revenues, but the company plans to ramp up its presence in Brazil and Germany to build momentum. Meanwhile, the field force in India has been downsized with an aim to defocus on older brands.

Jubilant Revenues Flat On LSI Decline

Jubilant reports higher second-quarter profits as it defers tax liability while revenues remain flat on the back of a decline in the LSI business and FDA action at two manufacturing units.

Jubilant Revenues Flat In Q2 On LSI Business Decline, FDA action

Jubilant reports higher second-quarter profits as it defers tax liability while revenues remain flat on the back of a decline in LSI business and FDA action at two manufacturing units.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC126093

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel